Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 5/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5005722 | 0.89 | OPRM1 (0.51) | HSP90AB1HSP90AA1OPRM1KMT2AHTT | |
| SCHEMBL5005512 | 0.87 | HSP90AB1 (0.51) | HSP90AB1HSP90AA1OPRM1ALDH1A1NPSR1 | |
| SCHEMBL17584093 | 0.85 | PARP1 (0.36) | HSP90AB1HSP90AA1PARP1DHODH | |
| SCHEMBL5005802 | 0.82 | HSP90AB1 (0.54) | HSP90AB1HSP90AA1OPRM1ALDH1A1NPSR1 | |
| SCHEMBL17584136 | 0.77 | DHODH (0.39) | OPRM1PARP1DHODH | |
| SCHEMBL5009923 | 0.76 | OPRM1 (0.52) | HSP90AB1HSP90AA1OPRM1 | |
| SCHEMBL17584087 | 0.72 | HSP90AA1 (0.35) | HSP90AB1HSP90AA1OPRM1PARP1 | |
| SCHEMBL5010057 | 0.71 | OPRM1 (0.52) | HSP90AB1HSP90AA1OPRM1 | |
| SCHEMBL3630113 | 0.71 | HSP90AB1 (0.51) | HSP90AB1HSP90AA1OPRM1ALDH1A1LMNA | |
| SCHEMBL1221094 | 0.69 | HSP90AB1 (0.60) | HSP90AB1HSP90AA1OPRM1ALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269193-A1 | Tetrahydroindole and Tetrahydroindazole Derivatives | SERENEX, INC. | 2008-10-30 | — | — | US | claimed |
| WO-2008130879-A2 | TETRAHYDROINDOLE AND TETRAHYDROINDAZOLE DERIVATIVES | SERENEX, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20080269193-A1 | Tetrahydroindole and Tetrahydroindazole Derivatives | SERENEX, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080269193-A1 | Tetrahydroindole and Tetrahydroindazole Derivatives | SERENEX, INC. | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269193-A1 | Tetrahydroindole and Tetrahydroindazole Derivatives | HSF1, HSP90AB1, TPH1 | HSP90AB1 2/4885HSP90AA1 4/4885OPRM1 2733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.